SN
Syndax Pharmaceuticals, Inc.
SNDX · NASDAQ
$17.62 -0.11% (-$0.02)
1M -9.96%
Market Cap $1.56B
P/E Ratio -
Div. Yield -
ROE 372.94%
Piotroski F-Score Weak
3/9Valuation
12 /100
Expensive P/S 6.20x
P/B 103.41x
P/E N/A
Growth
0 /100
Declining Book val. growth 48.29%
EPS growth N/A
Rev. growth N/A
Profitability
20 /100
Weak Gross margin 97.47%
Net margin 87.60%
FCF margin 87.64%
Quality
5 /100
Poor ROIC 32.12%
ROE 372.94%
Asset turnover 0.36x
Debt
23 /100
High Debt/Equity 39.03x
Current ratio 6.77x
Int. coverage -1.58x
Stability
54 /100
Moderate Beta 0.37x
EPS volatility 20.28%
Profitable years 0
Bulios Scoring descrie calitatea și istoricul unei companii, nu randamentul viitor. Un scor ridicat nu este un semnal de cumpărare. Află mai multe
Întreabă StockBot despre SNDX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Michael A. Metzger
Employees
298
Headquarters
New York City
Evenimente viitoare
02 NOV.
Earnings
Upcoming earnings report